Market Executive Summary

REPORT HIGHLIGHT
The drug device combination market is estimated to represent a global market of USD 75.8 billion by 2017 with growth rate of 9.8%. Rapid development of medical device and pharmaceutical industry have enabled the development of devices which incorporate drugs into it for effective application. These types of medical devices which enable to combine a therapeutics or biologic with a product, aiming to deliver drugs offers valuable approaches for treating life threatening chronic diseases.
Rising demand for minimally invasive procedures coupled with favorable government initiatives drive the market growth to great extent.Growing demand for drug device combination products due to its benefits such as minimal pain, heightened cost efficiency, safety, efficacy and rapid recovery and reduced hospital stay.
In terms of different products, drug device combination market is categorized as Orthopedic products,Inhalers, Photodynamic therapy devices, Infusion pumps, Transdermal patches, Drug eluting stents, Antimicrobial catheters and Others. The purpose of most of these combinational devices is to either boost the efficiency of devices or to provide product safety through better drug delivery. Among these different devices, transdermal patches and inhaler segment accounted for USD 61.28 billion in 2017 and is expected to dominate the total market collectively.Infusion pumps segment is further divided into Volumetric, Disposable, Syringe, Ambulatory and others.
Regionally, North America, and Europe dominated the global market. Rising research and development activities in this area stimulated the market growth in these regions. In 2017, North America recorded USD 38.23 billion and is expected to grow with 6.8% growth rate during the forecast period. Rising demand for drug combinational devices coupled with research and development initiatives will help the region to grow further at constant rate.
In Asia Pacific region, countries such as China and India shows their great potential to capture large share of the global market. TEH SENG Pharmaceutical Mfg. Co., Ltd., ProStrakan Group, Zhejiang Bangli Medical Products Co., Ltd., Zhejiang Yinda Biotechnology Co., Ltd., and Stemedica are some of the leading supplier and manufacturer of drug device combinations in China.
The market size and forecast for each segment has been provided for the period 2014 to 2028, considering 2017 as the base year. The report also provides the compounded annual growth rate (% CAGR) for the forecast period 2017 to 2028 for every reported segment.
The years considered for the study are:
Historical Year ? 2014 & 2017
Base Year ? 2017
Estimated Year ? 2017
Projected Year ? 2028
TARGET AUDIENCE
Traders, Distributors, And Suppliers
Manufacturers
Hospitals
Government and Regional Agencies and Research Organizations
Consultants
Distributors
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
MARKET,BY PRODUCT
Orthopedic products
Inhalers
Photodynamic therapy devices
Infusion pump
Transdermal patches
Drug eluting stents
Antimicrobial catheters
Others
MARKET, BY REGION
North America
Europe
Asia Pacific
Rest of the World
MARKET, BY COUNTRY
Further Breakdown of The North America Market
U.S.
Canada
Further Breakdown of The Europe Market
Germany
France
Rest of Europe
Further Breakdown of The APAC Market
India
China
Rest of APAC
Further Breakdown of The Rest of the World Market
Middle East and Africa
Latin America